Two groups of female bone cancer pain rats received intrathecal injection of normal saline (10 μL) and the specific CRF receptor antagonist α-helical CRF (9-41) (20 μg) [32, 59] respectively followed by cinobufagin (30 μg) 30 min later, and withdrawal thresholds were measured in both the contralateral and ipsilateral hindpaws prior to or post the last injection. This evidence concerns the gene CRH and bone cancer.